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ORIGINAL ARTICLE

Two phase 3, multicenter, randomized, placebo-controlled
clinical trials of fampridine-SR for treatment of spasticity
in chronic spinal cord injury
DD Cardenas1, JF Ditunno2, V Graziani3, AB McLain4, DP Lammertse5, PJ Potter6, MS Alexander7,
R Cohen8 and AR Blight8
Study design: Two randomized, double-blind, placebo-controlled trials.
Objective: To evaluate the efficacy and safety of fampridine sustained-release tablets (fampridine-SR) 25 mg twice daily for
moderate-to-severe spasticity in patients with chronic spinal cord injury (SCI).
Setting: United States and Canada.
Methods: Patients with incomplete chronic SCI were randomized to twice daily fampridine-SR 25 mg or placebo, with a 2-week
single-blind placebo run-in, a 2-week titration, 12 weeks of stable dosing, 2 weeks of downward titration and 2 weeks of untreated
follow-up. Co-primary end points were the change from baseline, averaged over the double-blind treatment period, for Ashworth score
(bilateral knee flexors and extensors) and a 7-point Subject Global Impression of treatment (SGI; 1, terrible; 7, delighted). Secondary
end points were: Penn Spasm Frequency Scale; the motor/sensory score from the International Standards for Neurological
Classification of SCI; Clinician’s Global Impression of Change of neurological status; and the International Index of Erectile Function
(men) or the Female Sexual Function Index (women).
Results: The populations were 212 and 203 patients in the two studies, respectively. Changes from baseline in Ashworth score were
0.15 (placebo) and 0.19 (fampridine-SR) in the first study, and 0.16 (placebo) and 0.28 (fampridine-SR) in the second
study. The between-treatment difference was not significant for either the Ashworth score or the SGI and, with few exceptions, neither
were the secondary end points. Fampridine-SR was generally well tolerated; treatment-emergent adverse events (TEAEs) and serious
TEAEs were reported with similar frequency between treatments.
Conclusion: Fampridine-SR was well tolerated. No significant differences were observed between treatment groups for the primary
end points of Ashworth score and SGI.
Spinal Cord (2014) 52, 70–76; doi:10.1038/sc.2013.137; published online 12 November 2013
Keywords: fampridine; dalfampridine; 4-aminopyridine; spasticity; sexual function; spinal cord injuries

INTRODUCTION
The concept of potassium channel blockade to improve conduction in
demyelinated nerve fibers has been pursued for over 30 years,
primarily with 4-aminopyridine. Animal studies indicate that
4-aminopyridine acts through restoration of action potential conduction in damaged nerve fibers, although it may also enhance synaptic
transmission and neuronal excitability.1,2 At concentrations of
1–10 mM, 4-aminopyridine broadly blocks voltage-dependent potassium channels, but its 50% inhibitory concentration values vary over
orders of magnitude across channel types.3 Few laboratory studies
demonstrated effects of 4-aminopyridine on potassium channels at
the submicromolar concentrations seen in human plasma following
clinically practical doses.4 This concentration dependence probably
explains its clinical effects in demyelinating conditions without

1Department

significant effects on cardiac function and little or no effect on
normal neurological function in most individuals.5
Several names have been used for 4-aminopyridine, including its
previous United States Adopted Name and current International
Nonproprietary Name of ‘fampridine’. At the time of the studies
described here, the ‘sustained release’ (SR) tablet formulation was
known by the provisional name ‘Fampridine-SR’. This same formulation, at a dose of 10 mg to be taken approximately every 12 h, was
approved by the United States Food and Drug Administration
to improve walking in people with multiple sclerosis based on
studies showing an increase in walking speed.6 The United States
Adopted Name was changed to ‘dalfampridine’ to avoid potential
name confusion and the formulation is referred to as ‘extended
release.’ In Europe, the same formulation is known as ‘fampridine
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prolonged-release’, although the terminology varies in other parts of
the world. In this paper, the formulation is referred to by the name
used at the time of the studies, ‘fampridine-SR’ and the active drug by
its chemical name, 4-aminopyridine, with respect to laboratory studies.
Several studies of fampridine that evaluated the effects on
neurological outcomes, including spasticity, in chronic spinal cord
injury (SCI) showed encouraging but mixed results.7–10 Spasticity,
one of the most common symptoms of SCI, affects patient function
and quality of life.11 The currently approved treatments are limited by
adverse effects and often require dosing as frequently as every 4 h.12
Measuring spasticity can be difficult because of variability in severity
over time, and the mix of hyperreflexia and muscle spasms.
In a phase 2 trial that compared 25 and 40 mg doses of fampridineSR against placebo, the 25 mg dose exhibited equivalent or better
efficacy for the primary end point of spasticity with better safety and
tolerability profiles as compared with the 40 mg dose.13 In addition,
some improvements with 25 mg fampridine-SR were observed relative
to placebo on secondary measures of bladder, bowel and sexual
functions. The two studies reported here evaluated the efficacy and
safety of fampridine-SR, 25 mg twice daily, for the treatment of
moderate-to-severe spasticity in patients with chronic, incomplete
SCI, regardless of concomitant treatment with other antispasmodic
medications.
MATERIALS AND METHODS
Study designs
Studies SCI-F301 and SCI-F302, of identical double-blind, placebo-controlled
design, were conducted at 45 and 33 centers, respectively, in the United States
and Canada; SCI-F301 was conducted from July 2002 to February 2004, and
SCI-F302 was conducted between June 2002 and November 2003. Both studies
received approval from Institutional Review Boards or ethics committees, and
were performed in accordance with the revised Declaration of Helsinki; all
patients or their legal representatives provided written informed consent.
Both studies consisted of a 2-week, single-blind placebo run-in, a 2-week
titration, 12 weeks of stable dosing, 2-week downward titration and 2 weeks of
untreated follow-up. Patients were randomized to fampridine-SR 25 mg or
placebo, twice daily, with treatment groups stratified by concomitant antispasmodic medication use to ensure that both groups included approximately
equal proportions of patients using these medications. Patients undergoing
physical therapy were permitted to continue their sessions during the study
only if there were no changes in the frequency of sessions or the methods used.

Patient populations
Men and women 18 to 70 years old were required to have chronic, incomplete,
traumatic SCI between C3 and T10 inclusive, defined as having occurred X18
months before screening; stable neurological status for X6 months; and
American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification grade B, C or D. Additional inclusion criteria were the presence of deep
tendon reflexes at the knees and bulbocavernosus or anal wink reflex; clinically
significant spasticity of the lower extremities, with average Ashworth Score of
42.0 on a scale of 1–5 (1, no increase in tone; 5, affected parts rigid in flexion
or extension) across the four muscle groups tested. Key exclusion criteria were
history of seizure; infection at screening; history of chronic urinary tract
infections; allergy to pyridine or tablet excipients; clinically significant
abnormal laboratory values or electrocardiogram at screening; injection with
botulinum toxin within 4 months of screening or with phenol or alcohol
within 12 months; and previous treatment with any 4-aminopyridine
formulation. Women were excluded if they were pregnant, lactating or of
childbearing potential and not using adequate birth control.

Efficacy end points
Efficacy was based on two co-primary end points: the change from baseline in
Ashworth score, averaged over the bilateral knee flexors and extensors, and a
7-point Subject Global Impression of treatment (SGI; 1, terrible; 7, delighted),

averaged over double-blind treatment. Baseline scores were the average of
values at the 1- and 2-week time points of the placebo run-in.
Secondary end points included the Penn Spasm Frequency Scale;14 the
motor/sensory score from the International Standards for Neurological
Classification of Spinal Cord Injury;15 Clinician’s Global Impression of
Change (CGI-C) of the patient’s neurological status, using a 7-point scale
(1, very much improved; 7, very much worse); and the International Index
of Erectile Function (IIEF)16 for men or the Female Sexual Function
Index17 for women. Bowel and bladder function outcomes were collected in
response to specific questions as part of a daily patient diary questionnaire
using an interactive voice response system. Questions included the number
of times per day the patient experienced accidental urination/leakage, the
number of bowel movements per day and the number of minutes per day
spent on bowel routine.

Enrolled and randomized (N=213)

ALLOCATION
Allocated to placebo (n=99)
Treated (n=98)

Allocated to fampridine-SR (n=114)
Treated (n=114)

FOLLOW-UP
Withdrew (n=13 [13.1%])
Protocol non-compliance
n=6
Adverse event
n=2
Request by subject
n=1
Lost to follow-up
n=2
Other
n=2

Withdrew (n=33 [28.9%])
Protocol non-compliance
n=5
Adverse event
n=20
Request by subject
n=3
Lost to follow-up
n=0
Other
n=5

ANALYSIS
Analyzed (n=98)
Completed (n=86 [86.9%])

Analyzed (n=114)
Completed (n=81 [71.1%])

Enrolled and randomized (N=204)

ALLOCATION
Allocated to placebo (n=100)
Treated (n=100)

Allocated to fampridine-SR (n=104)
Treated (n=103)

FOLLOW-UP
Withdrew (n=12 [12.0%])
Protocol non-compliance
n=1
Adverse event
n=2
Request by subject
n=5
Lost to follow-up
n=1
Other
n=3

Withdrew (n=26 [25.0%])
Protocol non-compliance
n=3
Adverse event
n=12
Request by subject
n=6
Lost to follow-up
n=1
Other
n=4

ANALYSIS
Analyzed (n=100)
Completed (n=88 [88.0%])

Analyzed (n=103)
Completed (n=78 [75.0%])

Figure 1 Disposition of patients in studies (a) SCI-F301 and (b) SCI-F302.
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Safety and tolerability evaluation
The safety population was defined as all randomized patients who received X1
dose of investigational drug. Evaluation of safety and tolerability was based on
the incidence and severity of treatment-emergent adverse events (TEAEs) and
changes in vital signs, laboratory values, electrocardiographic evaluation and
physical examination findings. TEAEs were any events during double-blind
treatment and up to 14 days after the last dose of investigational drug.

Statistical analysis
The modified intent-to-treat population, defined as all randomized patients
with X1 efficacy evaluation during double-blind treatment, was used for all
efficacy analyses, with last observation carried forward for imputation of
missing values. Between-treatment comparisons for all efficacy end points
except CGI-C were performed using an analysis of covariance model with
treatment, center and concomitant medication (use of antispasmodic drugs,
yes/no) as the main effects, and baseline as a covariate. Assessments of bladder,
bowel and sexual functions were secondary end points, although the studies
were not powered for these end points. Analysis of variance with treatment,
center and use of antispasmodic drug as the main effects was used for CGI-C.

Statement of ethics
We certify that all applicable institutional and governmental regulations
concerning the ethical use of human volunteers were followed during the
course of this research.

RESULTS
Study populations
In SCI-F301, 213 patients (99 placebo, 114 fampridine-SR) were
randomized, and in SCI-F302, 204 patients (100 placebo, 104
fampridine-SR) were randomized. Of these patients, 86.9 and
71.1% of the placebo- and fampridine-treated patients completed
SCI-F301 (Figure 1a); 88.0 and 75.0% of the respective groups
completed SCI-F302 (Figure 1b). The modified intent-to-treat
populations consisted of 212 and 203 patients from SCI-F301 and
SCI-F302, respectively; one placebo patient in SCI-F301 and one
fampridine-SR patient in SCI-F302 did not take any investigational
drug, and they were excluded from the analysis.
Demographic and clinical characteristics were balanced between
groups in each study except for a significantly higher score on the
ASIA Total Pin Prick subscore in the fampridine-SR group in
SCI-F302 (Table 1). Subjects were primarily male (84–88%) and
Caucasian (83–89%), with a mean (s.d.) age of 40.9 (12.5) years in
SCI-F301 and 40.9 (12.0) years in SCI-F302. Motor vehicle accidents
were the primary cause of injury (40.0–49.0%), followed by falls and
diving accidents.
The most frequent medications at baseline were antispasmodics
(for example, baclofen, tizanidine) that were used by 68.9 and 58.6%

Table 1 Baseline demographic and clinical characteristics of the patient populations in studies SCI-F301 and SCI-F302
Variable

Age, years, mean±s.d.
Gender, n (%)

SCI-F301

SCI-F302

Placebo (n ¼ 98 a)

Fampridine-SR (n ¼ 114)

P-value

Placebo (n ¼ 100)

Fampridine-SR (n ¼ 103 b)

P-value

40.1±13.1

41.6±12.1

0.372
0.830

40.5±12.3

41.3±11.8

0.669
0.620

86 (86.0)
14 (14.0)

86 (83.5)
17 (16.5)

Male
Female

85 (86.7)
13 (13.3)

100 (87.7)
14 (12.3)

Race, n (%)
Caucasian

81 (82.7)

94 (82.5)

87 (87.0)

92 (89.3)

12 (12.2)
2 (2.0)

18 (15.8)
0

10 (10.0)
0

8 (7.8)
1 (1.0)

1 (1.0)
2 (2.0)

1 (0.9)
1 (0.9)

0
3 (3.0)

0
2 (1.9)

57.0±25.1
78.1±3.8
68.2±27.7

53.8±26.6
75.7±23.0
65.2±26.9

0.460
0.427

53.6±26.2
72.5±24.1
56.6±28.2

59.1±25.0
76.3±21.9
64.2±26.3

28 (28.6)

42 (36.8)

0.357

32 (32.0)

32 (31.1)

32 (32.7)
38 (38.8)

29 (25.4)
43 (37.7)

30 (30.0)
38 (38.0)

26 (25.2)
45 (43.7)

48 (49.0)

49 (43.0%)

40 (40.0)

42 (40.8)

13 (13.3)
13 (13.3)

23 (20.2%)
10 (8.8)

18 (17.5)
16 (16.0)

16 (16.0)
16 (15.5)

13 (13.0)
7 (7.0)

7 (6.8)
4 (3.9)

8 (8.0)

16 (15.5)

5 (5.0)

9 (8.7)
1 (1.0)

Black
Asian/Pacific Islander
American Indian/Alaskan Native
Other
ASIA scores, mean±s.d.
Total motor score
Total light touch score
Total pin prick score
ASIA Impairment Scale, n (%)
B
C
D
Cause of injury, n (%)
Motor vehicle accident
Fall
Diving
Sports
Gunshot wound
Other
Special syndrome, n (%)

0.507

0.379

0.678

0.660

0.587

8 (8.2)
7 (7.1)

8 (7.0)
9 (7.9)

9 (9.2)

15 (13.2)

0.368

0.218
9 (7.9)
2 (1.8)

0.550

Brown-Séquard
Anterior cord

2 (2.0)
1 (1.0)

Mixed

1 (1.0)

0

4 (4.0)

1 (1.0)

5 (5.1)
69 (70.4)

3 (2.6)
77 (67.5)

3 (3.0)
62 (62.0)

4 (3.9)
57 (55.3)

Other
Use of antispasmodic medication, n (%)

0.125
0.244
0.046

0.653

0.335

Abbreviations: ASIA, American Spinal Injury Association; Fampridine-SR, fampridine suspended-release tablets.
aAlthough 99 patients were randomized to placebo, 1 patient in the placebo group did not take any investigational drug and was excluded from the evaluated patient population.
bAlthough 104 patients were randomized to fampridine-SR, 1 patient in the fampridine-SR group did not take any investigational drug and was excluded from the evaluated patient population.
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Efficacy
Although improvements on the Ashworth scale in both studies were
numerically better with fampridine-SR, the differences between
treatment groups in change from baseline for this and the co-primary
end point of SGI were small, and none of these differences achieved
statistical significance (Figure 2). Only minimal changes from baseline
were observed for the secondary end point of the Penn Spasm
Frequency Scale (Table 2), and the only significant difference between
treatments was on the Upper Extremity subscale in SCI-F302.
Changes in CGI-C scores were 0.1 to 0.2 points. No significant
differences were observed between treatments for the Total Motor
Score in either study; adjusted changes from baseline were 1.7 for
placebo and 1.2 for fampridine-SR in SCI-F301, and 0.7 and 0.4,
respectively, in SCI-F302.
On sexual dysfunction measures, the only significant betweentreatment differences were for a slightly greater improvement
observed among men treated with fampridine-SR on two IIEF
domains, erectile function (P ¼ 0.016) and orgasmic function
(P ¼ 0.032) in SCI-F301 (Table 3).
No significant differences between treatments were observed for
bladder and bowel function in SCI-F301, although there was a
significantly greater increase with fampridine-SR relative to placebo
for the number of bowel movements in SCI-F302 (P ¼ 0.006; Table 4).
Safety and tolerability
The incidence of TEAEs was similar between treatment groups in
SCI-F301, 85.7 and 82.5% for placebo and fampridine-SR, respectively, but it was slightly higher with fampridine-SR (95.1%) relative
to placebo (83.0%) in SCI-F302 (Table 5). TEAEs were generally of
mild or moderate severity. Serious TEAEs were reported with a
similar frequency in placebo and fampridine-SR groups in both
studies (Table 5). The single death, a placebo-treated patient in SCIF302, was caused by atherosclerotic disease complicated by morphine
intoxication and was considered unrelated to treatment by the
investigator.
In SCI-F301, 3 (3.1%) placebo and 19 (16.7%) fampridine-SR
patients discontinued because of TEAEs (Table 5). Within the
fampridine-SR group, the most common TEAEs leading to discontinuation were dizziness (6.1%) and hypertonia, insomnia and asthenia
(2.6% each). Similar proportions and reasons for TEAE-related discontinuations were reported in SCI-F302; 3 (3.0%) and 16 (15.5%)
patients in the placebo and fampridine-SR groups, respectively, with
dizziness (3.9%), hypertonia (2.9%) and paresthesia (2.9%) the most
common TEAEs leading to discontinuation for fampridine-SR.
In both studies, fampridine-SR had a higher frequency of TEAEs
considered possibly or probably related to treatment relative to
placebo: 43.0% vs 24.5% in SCI-F301 and 48.5% vs 25.0% in SCIF302 (Table 5). The most common TEAEs with fampridine-SR

Placebo Fampridine(n =96) SR (n =109)

Study SCI-F302
Placebo
(n =98)

FampridineSR (n =102)

0
Mean (SE) Change in Ashworth Score

Adherence to treatment
Therapy adherence was high; 95.9% of placebo and 84.2% of
fampridine-SR patients had X80% adherence in SCI-F301, with
94.9 and 84.5%, respectively, in SCI-F302.

Study SCI-F301

–0.05
–0.10
–0.15
–0.20

–0.15
–0.16
–0.19

–0.25
–0.30

P =0.439
–0.28

–0.35

P =0.069
Study SCI-F301

0.10
Mean (SE) Change in SGI Score

of patients in SCI-F301 and SCI-F302, respectively (Table 1). Use of
concomitant medications was similar between treatment groups and
consistent between the studies, and concomitant use of baclofen was
reported during double-blind treatment by 63.3% of placebo patients
and 54.4% of fampridine-SR patients in SCI-F301, and by 54.0 and
47.1% in SCI-F302.

Placebo Fampridine(n =96) SR (n =109)

Study SCI-F302
Placebo Fampridine(n =98) SR (n =102)

0.05
0
–0.05
–0.10

0

–0.15
–0.20
–0.1

–0.1
–0.25

P =0.310

–0.30
–0.2
P =0.623
Figure 2 Adjusted change from baseline, averaged over the double-blind
treatment period, for the co-primary end points of (a) Ashworth Spasticity
Scale scores and (b) SGI of treatment.

included urinary tract infection, hypertonia, dizziness, pain and
constipation (Table 5).
Several patients in both studies had clinically significant changes in
laboratory values, but no trends were observed for between-treatment
differences for type or frequency of changes. Both groups had similar
percentages of patients with potentially significant changes in heart
rate-corrected QT values (prolongation X30 ms) during the study:
12.6% and 12.4% of placebo and fampridine-SR patients, respectively.
DISCUSSION
The design of these two phase 3 trials was based on the previous phase
2 trial13 with respect to dose selection, primary outcome measures
and recruitment criteria. In post-hoc analyses, the earlier study showed
significant improvements in Ashworth score among subjects who had
more than minimal spasticity at baseline. Therefore, these studies
prospectively recruited individuals with an average Ashworth score of
Spinal Cord
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Table 2 Adjusted change from baseline on the Penn Spasm Frequency Scale in studies SCI-F301 and SCI-F302
SCI-F301

Placebo (n ¼ 95)

SCI-F302

Fampridine-SR (n ¼ 107)

P-value

Placebo (n ¼ 98)

Fampridine-SR (n ¼ 102)

P-value

Baseline,

Change,

Baseline,

Change,

Baseline,

Change,

Baseline,

Change,

mean±s.d.

mean±s.e.

mean±s.d.

mean±s.e.

mean±s.d.

mean±s.e.

mean±s.d.

mean±s.e.

0.91±1.00
2.24±0.91

0.06±0.05
0.02±0.06

1.00±1.08
2.30±1.02

0.07±0.04
0.05±0.06

0.821
0.742

1.11±1.06
2.37±1.07

0.02±0.05
0.10±0.05

0.85±0.95
2.12±1.04

0.13±0.05
0.12±0.05

0.044
0.859

0.78±0.84
2.15±0.68

0.04±0.04
0.07±0.04

0.85±0.90
2.07±0.67

0.05±0.04
0.10±0.04

0.891
0.693

0.89±0.83
2.08±0.68

0.02±0.04
0.07±0.04

0.75±0.80
2.18±0.66

0.09±0.03
0.14±0.04

0.108
0.233

Spasm frequency
Upper extremity
Lower extremity
Spasm severity
Upper extremity
Lower extremity

Abbreviation: Fampridine-SR, fampridine suspended-release tablets.

Table 3 Adjusted change from baseline at the end of double-blind treatment for sexual function using the IIEF and the FSFI in studies
SCI-F301 and SCI-F302
Mean change±s.e. (n)
SCI-F301

SCI-F302

Placebo

Fampridine-SR

P-value

1.5±0.9 (74)
0.7±0.4 (73)
0.1±0.2 (74)
0.7±0.4 (74)
0.1±0.3 (60)

1.5±0.9 (71)
0.5±0.4 (72)
0.1±0.2 (71)
0.4±0.4 (72)
0.2±0.3 (62)

0.016
0.032

0.7±0.3 (11)
0.4±0.4 (11)
0.1±0.6 (10)
0.5±0.4 (11)

0.298

Placebo

Fampridine-SR

P-value

1.6±1.0 (77)
0±0.3 (76)
0±0.2 (75)
0.4±0.5 (76)
0.3±0.2 (66)

0.8±1.1 (65)
0.3±0.4 (64)
0±0.2 (64)
0.4±0.6 (64)
0.4±0.3 (51)

0.572
0.554

0.2±0.3 (13)
0.2±0.4 (13)
0.2±0.5 (13)
0.4±0.2 (13)

0.7±0.3 (14)
0.6±0.4 (14)
0.7±0.5 (14)
0.2±0.2 (14)

0.258

0.3±0.3 (12)
0.1±0.5 (13)

0.4±0.3 (13)
0.7±0.5 (14)

IIEF
Erectile function
Orgasmic function
Sexual desire
Intercourse satisfaction
Overall satisfaction
FSFI
Desire
Arousal
Lubrication
Orgasm
Satisfaction
Pain

0.4±0.3
0.7±0.3
0.7±0.6
0.6±0.4

(12)
(12)
(13)

(13)
0.8±0.4 (12)
0.6±0.7 (12)

0±0.4 (11)
0.1±0.8 (11)

0.669
0.058
0.943

0.496
0.228
0.903
0.106
0.483

0.843
0.956
0.632

0.526
0.146
0.308
0.925
0.260

Abbreviations: Fampridine-SR, fampridine suspended-release tablets; FSFI, Female Sexual Function Index; IIEF, International Index of Erectile Function.

Table 4 Adjusted change from baseline, averaged over the double-blind treatment period, for Bladder/Bowel Function Diary Scores in studies
SCI-F301 and SCI-F302
SCI-F301
Placebo (n ¼ 97)
Baseline,

Change,

SCI-F302

Fampridine-SR (n ¼ 114) P-value
Baseline,

Change,

mean±s.d. mean±s.e. mean±s.d. mean±s.e.
Number of accidental urinations or leakages
Number of bowel movements
Number of minutes spent on bowel routine

Baseline,

Change,

mean±s.d.

mean±s.e.

Fampridine-SR (n ¼ 103) P-value
Baseline,

Change,

mean±s.d. mean±s.e.

0.7±2.0 0.1±0.1 0.7±2.0
0.0±0.1 0.095 0.6±2.3 0.2±0.2
1.4±4.0
0.2±0.2 0.932
0.7±0.4
0.0±0.0 0.7±0.5
0.0±0.0 0.082 0.7±0.5 0.0±0.0
0.8±0.6
0.1±0.0 0.006
23.8±24.2 2.7±1.0 21.3±18.5 1.0±0.9 0.159 19.3±18.1 0.3±0.93 19.2±16.3 0.7±0.9 0.437

Abbreviation: fampridine-SR, fampridine suspended-release tablets.
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Table 5 Incidence of TEAEs in studies SCI-F301 and SCI-F302
Adverse event

Incidence, n (%)
SCI-F301a

Any TEAE

SCI-F302

Placebo

Fampridine-SR

Placebo

Fampridine-SR

(n ¼ 98)

(n ¼ 114)

(n ¼ 100)

(n ¼ 103)

84 (85.7)

94 (82.5)

83 (83.0)

98 (95.1)

Serious TEAEs
Deaths

6 (6.1)
0

6 (5.3)
0

9 (9.0)
1 (1.0)

8 (7.8)
0

Discontinuation due
to TEAEs

3 (3.1)

19 (16.7)

3 (3.0)

16 (15.5)

24 (24.5)

49 (43.0)

25 (25.0)

50 (48.5)

Treatment-related
TEAEsb

Most common TEAEsc
Urinary tract
infection

16 (16.3)

34 (29.8)

15 (15.0)

22 (21.4)

Hypertonia
Dizziness

25 (25.5)
3 (3.1)

23 (20.2)
15 (13.2)

17 (17.0)
1 (1.0)

24 (23.3)
12 (11.7)

Pain
Constipation

14 (14.3)
8 (8.2)

13 (11.4)
11 (9.6)

14 (14.0)
10 (10.0)

19 (18.4)
19 (18.4)

Accidental injury
Headache

17 (17.3)
8 (8.2)

10 (8.8)
10 (8.8)

16 (16.0)
8 (8.0)

9 (8.7)
15 (14.6)

Nausea
Paresthesia

4 (4.1)
5 (5.1)

10 (8.8)
10 (8.8)

6 (6.0)
9 (9.0)

9 (8.7)
18 (17.5)

Insomnia
Asthenia

3 (3.1)
4 (4.1)

10 (8.8)
9 (7.9)

6 (6.0)
6 (6.0)

16 (15.5)
3 (2.9)

Back pain
Infection

6 (6.1)
10 (10.2)

9 (7.9)
9 (7.9)

3 (3.0)
15 (15.0)

10 (9.7)
11 (10.7)

Diarrhea
Dyspepsia

8 (8.2)
2 (2.0)

8 (7.0)
8 (7.0)

7 (7.0)
5 (5.0)

2 (1.9)
5 (4.9)

0
10 (10.2)

8 (7.0)
7 (6.1)

2 (2.0)
3 (3.0)

5 (4.9)
4 (3.9)

Nervousness
Arthralgia
Rash

3 (3.1)

7 (6.1)

7 (7.0)

5 (4.9)

Skin ulcer
Sweating

7 (7.1)
1 (1.0)

7 (6.1)
7 (6.1)

5 (5.0)
3 (3.0)

5 (4.9)
5 (4.9)

Anxiety
Urinary

1 (1.0)
5 (5.1)

6 (5.3)
6 (5.3)

1 (1.0)
4 (4.0)

5 (4.9)
4 (3.9)

incontinence
Abdominal pain

4 (4.1)

5 (4.4)

5 (5.0)

10 (9.7)

Peripheral edema
Fever

2 (2.0)
2 (2.0)

3 (2.6)
5 (4.4)

9 (9.0)
5 (5.0)

7 (6.8)
6 (5.8)

—

—

6 (6.0)

6 (5.8)

Pharyngitis

Abbreviations: Fampridine-SR, fampridine suspended-release tablets; TEAE, treatmentemergent adverse event.
aTEAEs include adverse events during double-blind treatment and up to 14 days after the last
dose of investigational drug.
bTEAEs considered by the investigator to be possibly or probably related to treatment; TEAEs
with missing investigational drug relationship were classified as ‘related’.
cBy Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) preferred term
occurring in X5% of fampridine-SR-treated patients in either study.

42.0. Two positive studies are normally required for regulatory
approval.
No significant differences between treatments were observed in
either study for the two co-primary end points, change from baseline
of the Ashworth and SGI scores, averaged over the double-blind
period. The SGI was used as a co-primary end point to determine the
clinical meaningfulness of any changes in Ashworth score and to assess
patient perceptions of potential negative drug effects that might have
counterbalanced benefits. Thus, the SGI results can be considered to
represent a mixed response, as there was neither a positive nor negative

change in the mean score. The previous phase 2 study reported
significantly improved SGI scores with fampridine-SR-treated relative
to placebo but no significant difference in Ashworth score change,
except for the subset of patients with more marked spasticity.13
Although the greater improvement in the Upper Extremity Spasm
Frequency subscale with fampridine-SR compared with placebo in
SCI-F302 was nominally significant (P ¼ 0.044), there were no other
significant between-treatment differences on the Penn Spasm Frequency Scale in either study. Self-report and clinical examination
scales for spasticity assessment may represent different dimensions of
the clinical problem of spasticity. In this regard, the Penn Spasm
Frequency Score correlates significantly with clonus or perceived
problematic spasticity that interferes with activities of daily living, and
may not reflect the single-joint, velocity-dependent resistance to
movement, as measured by the Ashworth scale.18,19
With respect to sexual function end points, no significant
differences were observed between treatments for sexual function
among women in either trial. Among men in SCI-F301, two IIEF
domains were significantly improved at end point with fampridineSR relative to placebo, erectile function (P ¼ 0.016) and orgasmic
function (P ¼ 0.032), and another domain (intercourse satisfaction)
trended toward significance (P ¼ 0.058). Although these results are
similar to the phase 2 trial,13 sexual function was neither a primary
focus of the current studies nor an inclusion criterion. Also, the
nominal significance, achieved only in SCI-F301, was with end point
analysis rather than the prespecified analysis of change from baseline
averaged over double-blind treatment.
Although 25 mg twice daily is a higher dose than approved for the
treatment of walking impairment in patients with multiple sclerosis,20
the safety profile was generally consistent with previous studies
evaluating fampridine-SR for SCI and multiple sclerosis.6,13 There
were no seizure-related TEAEs in either trial.
In summary, fampridine-SR 25 mg twice daily was generally well
tolerated in patients with chronic incomplete SCI. However, no
significant differences were observed between treatment groups for
the primary end points. Although the efficacy reported in the phase 2
trial could not be confirmed, it is possible that functionally related
end points may be necessary to observe effects. Interpretation of
nominally significant changes on other end points should be made
with caution, as these end points were not prospectively defined as
part of the primary analysis of either study and represent subanalyses
among multiple potential end points. It should also be noted that
other than stable physical therapy regimens that had previously been
initiated, these studies did not specifically include instructed activity
such as physical therapy, range of motion or other physical interventions that have been endorsed as adjunctive to pharmacologic
management of spasticity; insufficient data were available for analyzing the subset of patients undergoing physical therapy. Nevertheless,
the overall results of previous studies and those reported here suggest
that further evaluation of fampridine-SR may be warranted in
patients with SCI. These evaluations could potentially build on the
observation from studies in multiple sclerosis patients that only a
subset of treated individuals respond to treatment.6
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